HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Lussanet, Q. G. Articles by Beets-Tan, R. G. H. Search for Related Content PubMed PubMed Citation Articles by de Lussanet, Q. G. Articles by Beets-Tan, R. G. H.

Gadopentetate Dimeglumine versus Ultrasmall Superparamagnetic Iron Oxide for Dynamic Contrast-enhanced MR Imaging of Tumor Angiogenesis in Human Colon Carcinoma in Mice¹

¹ From the Department of Radiology (Q.G.d.L., W.H.B., J.M.A.v.E., R.G.H.B.T.) and Angiogenesis Laboratory of Internal Medicine (A.W.G.), Maastricht University Hospital, P. Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, the Netherlands. From the 2002 RSNA scientific assembly. Received August 15, 2002; revision requested September 24; final revision received March 20, 2003; accepted April 7. Supported in part by the Cardiovascular Research Institute Maastricht (CARIM), the Netherlands. Address correspondence to Q.G.d.L. (e-mail: qdlu@rdia.azm.nl).

PURPOSE: To compare the kinetic physiologic properties of a clinical contrast agent, gadopentetate dimeglumine, with those of ultrasmall superparamagnetic iron oxide (USPIO) particles for dynamic contrast material–enhanced magnetic resonance (MR) imaging of tumor angiogenesis in human colon carcinoma in mice with a clinical MR imaging unit.

MATERIALS AND METHODS: Thirty-two mice with human colon carcinoma were injected with either gadopentetate dimeglumine (n = 16) or USPIO (n = 16) for dynamic contrast-enhanced MR imaging and pre- and postcontrast T2 and T2* measurements. Dynamic contrast-enhanced MR imaging measurements were analyzed by using a two-compartment model to calculate the endothelial transfer coefficient surface area product (K^PS) for the tumor microvasculature, the reflux coefficient (k), and the fractional plasma volume (f^PV). K^PS, k, and f^PV maps were compared with histologic microvessel density (MVD) and used to observe differences between core and rim regions of tumor.

RESULTS: Results in 30 mice (15 in the gadopentetate dimeglumine group and 15 in the USPIO group) could be used. K^PS values measured with both agents correlated well with MVD in hot spots (gadopentetate dimeglumine: r = 0.6, P = .02; USPIO: r = 0.6, P = .01). No significant difference (P = .4) in correlation was found between the two agents. Both USPIO and gadopentetate dimeglumine demonstrated higher MVD and K^PS values in tumor rim than in tumor core (P < .01). Tumor k values correlated poorly with whole-tumor MVD for both gadopentetate dimeglumine (r = 0.3, P = .4) and USPIO (r = 0.2, P = .6), while f^PV values correlated well with whole-tumor MVD for USPIO (r = 0.6, P = .02) but not gadopentetate dimeglumine (r = -0.01, P = .98). T2 and T2* measurements showed small differences between areas of high and low angiogenic activity with both agents.

CONCLUSION: The kinetic physiologic properties of gadopentetate dimeglumine are as good as those of USPIO for dynamic contrast-enhanced MR imaging for calculating K^PS as a measurement of angiogenesis in human colon carcinoma. Further studies with patients may reveal whether gadopentetate dimeglumine might be used for this purpose in clinical practice.

© RSNA, 2003

Index terms: Angiogenesis • Animals • Contrast media, comparative studies • Magnetic resonance (MR), contrast media • Magnetic resonance (MR), relaxometry • Neoplasms, blood supply • Neoplasms, experimental studies

This article has been cited by other articles:

				A. J. de Langen, V. E. M. van den Boogaart, J. T. Marcus, and M. Lubberink Use of H215O-PET and DCE-MRI to Measure Tumor Blood Flow Oncologist, June 1, 2008; 13(6): 631 - 644. [Abstract] [Full Text] [PDF]

				M. van Vliet, C. F. van Dijke, P. A. Wielopolski, T. L. M. ten Hagen, J. F. Veenland, A. Preda, A. J. Loeve, A. M. M. Eggermont, and G. P. Krestin MR Angiography of Tumor-related Vasculature: From the Clinic to the Micro-environment RadioGraphics, October 1, 2005; 25(suppl_1): S85 - S97. [Abstract] [Full Text] [PDF]

				Q. G. de Lussanet, S. Langereis, R. G. H. Beets-Tan, M. H. P. van Genderen, A. W. Griffioen, J. M. A. van Engelshoven, and W. H. Backes Dynamic Contrast-enhanced MR Imaging Kinetic Parameters and Molecular Weight of Dendritic Contrast Agents in Tumor Angiogenesis in Mice Radiology, April 1, 2005; 235(1): 65 - 72. [Abstract] [Full Text] [PDF]

				A R Padhani MRI for assessing antivascular cancer treatments Br. J. Radiol., December 1, 2003; 76(suppl_1): S60 - S80. [Abstract] [Full Text] [PDF]